

Changes in Cochlear Implant Candidacy and Future Innovations

Michelle L. Hughes, PhD, CCC-A, Professor

Tessa Boesiger, AuD, CCC-A, Assistant Professor of Practice

Department of Special Education and Communication Disorders
University of Nebraska-Lincoln

Iowa Conference on Communication Disorders, April 11, 2025



Introductions



Michelle Hughes, PhD, CCC-A
Professor



Tessa Boesiger, AuD, CCC-A
Assistant Professor of Practice





Session Outline

- A brief history of CIs
- Expanded CI candidacy criteria:
 - Age at implant
 - Degree of hearing loss
- What is on the Horizon?
- Conclusions and Questions/Discussion



Part 1

**A Brief History of Cochlear
Implants – The “Firsts”**



Early 1800's



1972



©2012 House Resonance

First successful
single-channel CI
(FDA approval
1984)




Fig. 3. Bipolar reed contact system before encapsulation.




Fig. 4. Bipolar reed contact system after encapsulation.

First multichannel CI implanted in Vienna

(Burian et al. 1979)

1977



Outcomes of single-channel vs. multi-channel CIs


TABLE 2. *Open-set sentences > 6 months postimplant/reimplant*

	Single-channel		Multichannel		
	%	Time	%	Time	Strategy*
CID or Iowa sentences					
Patient 1	0	7 mos	45	6 mos	F0F1F2
Patient 2	4	5 yrs	78	6 mos	SPEAK
Patient 3	0	7 mos	9	6 mos	F0F1F2
Lindeman et al ¹⁶	1	21 mos	31	18 mos	F0F1F2
Japanese sentences					
1, Gyo et al ⁶	4	5 yrs	23	6 mos	SPEAK
2, Gyo et al ⁶	0	7 yrs	92	6 mos	SPEAK

*F0F1F2 and SPEAK refer to the speak processing strategy used by the multichannel device.

(Rubinstein et al. 1998)

NU - 6 Audio Tape (Open - Set) (MAC)



Outcomes of single-channel vs. multi-channel CIs





Fig. 4. Performance scores—NU-6 (MAC Battery) Sound-Only. LA = Los Angeles implant, V = Vienna implant, M = Melbourne implant, (prime indicates F1F2 speech processor), U = Utah implant, SF = San Francisco implant.

Multi-channel

(Tyler et al. 1988)

1996




First bilateral CIs implanted in Vienna

(Helms et al. 1997)


Bilateral CI Outcomes: Localization Patterns

(Litovsky et al. 2004, Fig. 1)



Bilateral CI Outcomes: Localization Patterns

(Litovsky et al. 2004, Fig. 2)



Bilateral CI Outcomes: Speech Recognition in Noise

(Wolfe et al. 2007, Fig. 5)




FIG. 5. Mean results for speech recognition in noise assessment. The SNR₅₀ is provided for three conditions: (A) when only the first cochlear implant is used; (B) when only the second cochlear implant is used, and (C) when both cochlear implants are used. Bilateral benefit is defined as the difference in SNR₅₀ between the first ear condition and the bilateral condition.


1999

Electric-Acoustic Stimulation of the Auditory System

New Technology for Severe Hearing Loss

C. von Ilberg^a J. Kiefer^a J. Tillein^b T. Pfenningdorff^a R. Hartmann^b
E. Stürzebecher^a R. Klinke^b

Departments of ^aOtorhinolaryngology and ^bPhysiology, Johann Wolfgang Goethe University,
Frankfurt/Main, Germany



First electroacoustic stimulation (EAS) device implanted


(von Ilberg et al. 1999)



DEPARTMENT OF SPECIAL EDUCATION
AND COMMUNICATION DISORDERS

First CI surgery for tinnitus in single-sided deafness

(van de Heyning et al. 2008)



2003

Annals of Otology, Rhinology & Laryngology 117(9):645-652.
© 2008 Annals Publishing Company. All rights reserved.

Incapacitating Unilateral Tinnitus in Single-Sided Deafness Treated by Cochlear Implantation

Paul Van de Heyning, MD, PhD; Katrien Vermeire, PhD; Martina Diebl, MS;
Peter Nopp, PhD; Ilona Anderson, BA; Dirk De Ridder, MD, PhD


N

DEPARTMENT OF SPECIAL EDUCATION
AND COMMUNICATION DISORDERS

First CI surgery for single-sided deafness

(van de Heyning et al. 2008)

2003



First totally implantable CI

(Briggs et al. 2008)

2005




FIG. 1. *A*, The TIKI implant showing electrode array, microphone, receiver coil, magnet, and extracochlear plate electrode and ball electrode. *B*, With the CI24RE Freedom for comparison.



Otology & Neurotology, Vol. 29, No. 2, 2008

2005



First totally implantable CI

(Briggs et al. 2008)

CNC word score in quiet (60 dB SPL RMS)



CUNY sentence score in noise (65 dB SPL RMS)




Part 2A

**Expanded Cochlear Implant
Candidacy Criteria:
Age at Implant**



1985



Nucleus 22 with WSP

FDA approval of first multichannel CI for post-lingually deafened adults

TABLE 1. CENTRAL INSTITUTE FOR THE DEAF EVERYDAY SENTENCE TEST

Patient	Percent of Key Words Correct		Difference
	F0/F2	F0/F1/F2	
1	54	90	+ 36
2	38	70	+ 32
3	31	54	+ 23
4	16	62	+ 46
5	10	26	+ 16
6	20	38	+ 18
7	44	100	+ 56
Mean	30.4	62.9	+ 32.4

$t = 5.79, df = 6, p = 0.01.$


Dowell et al. (1987)



1990



FDA approval for
children aged 2
years and up




Nucleus 22 with MSP

1998



Nucleus Esprit

- First BTE processor
- First CI with eCAP telemetry
- Implant age reduced to 18 months



Nucleus Neural Response Telemetry



2000



Implant age for CI
reduced to 12
months

Cochlear receives FDA approval to lower the age of pediatric cochlear implantation to 9 months

Approval underscores necessity of earlier cochlear implantation for better hearing, speech and language outcomes in children born deaf

Centennial, Colo. (March 18, 2020) — Cochlear Limited (ASX: COH), the global leader in implantable hearing solutions, obtained U.S. Food and Drug Administration (FDA) approval to lower the age of cochlear implantation from 12 months to 9 months for children with bilateral, profound sensorineural hearing loss. This approval ensures children born deaf have earlier access to a cochlear implant which can provide them with the hearing capabilities to develop speech and language at a trajectory similar to their hearing peers.



Implant age
reduced to 9
months

2020



Expanded CI Candidacy

- **1985:** Adults with bilateral profound SNHL
- **1990:** Addition of children 2 years and up (profound HL only)
- **1998:** Age lowered to 18 months (profound only)
- **2000:** Age lowered to 12 months (profound); allowed for severe-profound for 2+ years
- **2013:** First EAS device approved for adults with residual low frequency hearing
- **2019:** Inclusion of SSD/AHL for 5 years and up
- **2020:** Age lowered to 9 months (traditional CI)



Expanded CI Candidacy: 9 months

- 10 years of research to lower age from 2 years to 1 year
- 20 years to lower age from 1 year to 9 months
- Primary concerns:
 - Accurate estimates of hearing thresholds
 - Accurate estimates of functional outcomes with amplification
 - Safety (anesthetic/surgical risks)
 - Post-operative CI programming




Accurate Estimates of Acoustic Thresholds

- Tymps and reflexes
- ABR (exercise caution with ANSD!)
- OAE
- VRA starting ~6 months
- Etiology, imaging, genetic testing

Bottom line: Ensure we do not implant children who are not deaf!





Accurate Estimates of Functional Outcomes

- Can't use standard benchmarks of aided word recognition to assess HA benefit
- Can use IT-MAIS, LittleEars parent inventories



Surgical/ Anesthetic Risks

- No difference in the incidence of perioperative complications between children aged 1-12 months and those aged 1-5 years across various types of surgeries (Cohen et al. 1990)
- Similar findings for studies specific to CI surgery for <12 months vs. >12 months (e.g., Lesinski-Schiedat et al. 2004; Roland et al. 2009; Cosetti & Roland 2010; Chweya et al. 2021)
- Use of pediatric anesthesiologist significantly decreases risk of perioperative complications (Keenan et al. 1991)
- Challenges associated with anatomical differences require knowledgeable and experienced surgeons.

Post-Operative Programming

- Combined use of behavioral (VRA) and objective measures
 - Telemetry
 - Electrode impedance
 - eCAP
 - eSRT
 - eABR





Evidence Supporting Younger Age of Implantation

- More cost effective for CI <12 months than for 12-23 months (Colletti et al. 2011).
- Higher scores on receptive and expressive spoken language outcomes for children implanted:
 - Between 12-24 months versus those implanted one year later (Miyamoto et al. 2008)
 - Between 6-11 months and those implanted between 12-18 months (Nicholas & Geers 2013; Dettman et al. 2016) or later.



Evidence Supporting Younger Age of Implantation



Top: Nicholas & Geers (2013), Figure 1
Bottom: Dettman et al. (2016), Figure 4



**Auditory
Comprehension**

Evidence Supporting Younger Age of Implantation


**Expressive
Language**



Preschool Language Scales


Evidence Supporting Younger Age of Implantation

CELF-4



Evidence Supporting Younger Age of Implantation

Speech Recognition



Part 2B

**Expanded Cochlear Implant
Candidacy Criteria:
Degree of Hearing Loss**




Future Directions: Expanding Degree of HL

- Current Criteria for Adults:
 - Moderate-profound SNHL
 - $\leq 50\%$ sentences ear to implant, $\leq 60\%$ best aided
- Current Criteria for Children:
 - Profound SNHL < 2 yrs, severe-profound SNHL > 2 yrs
 - $\leq 30\%$ words



2013



FDA approval of EAS

EAS Hearing Preservation




FIG. 1. Ipsilateral pure-tone audiometric data of the EAS group (n = 10) for various intervals before and after surgery. One subject lost hearing completely, and data from this subject have not been included in this graph.

EAS Hearing Preservation




FIG. 1. Hearing threshold medians and interquartile ranges for the time intervals: preoperative (*black dashed line, circles*), postoperative (*gray dotted line, triangles*), and 12 months (*red solid line, squares*); n denotes number of subjects for each condition.

EAS Hearing Preservation




FIG. 2. Panel A: Pure-tone averages for low frequencies (PTA_{low}; mean of air conduction thresholds for 125 Hz, 250 Hz, and 500 Hz) shown as box plots (median, 1st and 3rd quartiles, minimum and maximum values, *circles* indicate outliers, *n* denotes number of subjects for each condition). Long-term is >24 months, mean, 51.4 months, range, 2–11 years. Panel B: Scatter plot of long-term (>24 months) shifts of pure-tone averages for low frequencies (PTA_{low}; mean of air conduction thresholds for 125 Hz, 250 Hz, and 500 Hz) with regard to preoperative PTA_{low}. Linear regression (*dashed line*, $y = 16.02 + 0.13x$, $R^2 = 0.053$) shows a trend of residual hearing deterioration for this population sample ($n = 40$).

EAS Performance






FIG. 3. CNC word scores 3 and 6 months after fitting for both groups. Differences with a p value of less than .05 are considered statistically significant.

Expanding Degree of HL: Children



Teagle et al. (2019), Fig. 5, N = 1,570 children

Expanding Degree of HL: Children



- Carlson et al. (2015):
 - Examined performance for 51 children implanted outside standard criteria
 - 63% improvement in speech recognition in CI ear and 40% improvement bimodal (mean 17 months post-CI)
- Teagle et al. (2019): 76% average word score post CI



Single-Sided Deafness

Outline:

- Review of binaural hearing mechanisms
- How SSD impacts auditory development
- Considerations for candidacy and fitting
- Outcomes



2019



Med-El Synchrony

FDA approval of CI
for single-sided
deafness

Binaural Hearing Mechanisms

- Spatial hearing abilities developed by 4 – 5 years in NH
- Primary sequela of SSD: lack of binaural hearing development
 - Sound localization
 - Head-shadow (ITD, ILD)
 - Binaural squelch
 - Binaural summation




Fig. 1, Litovsky et al. (2012), JAAA

Binaural Hearing Mechanisms

- Functional sequelae:
 - Sound source segregation/listening in noise
 - Incidental learning
 - Cognitive load
 - Listening fatigue
 - Educational progress




Effects of SSD on Auditory Development

- Cortical reorganization with early SSD
- Lack of development of binaural processing
- Cortical EEG studies show preference for NH ear early on (Lee 2020)
- Goal for implantation: development of binaural hearing mechanisms



- Treatment options: CROS via air or bone (BC HA or OIAI), CI

CROS



BCHA



BAHA/
OIAI



CI



Considerations for SSD CI Candidacy

- Treatment options: CROS via air or bone (BC HA or OIAI), CI




Fig. 3a, Arndt et al. (2017) HNO

N=45 adults with SSD



Considerations for SSD CI Candidacy

- Localization abilities with different tx options:




Fig. 3c, Arndt et al. (2017) HNO


N=45 adults with SSD

Considerations for SSD CI Candidacy

- Etiology
 - CND (~25% cases, Dewyer et al. 2021; 58%, Arndt et al. 2015)
 - CCMV (67% cases; Lee et al. 2021)
 - ~2/3 of SSD cases are potential CI candidates
- Age (development of binaural hearing)
- Test conditions must exploit binaural mechanisms
- Med-El Synchrony 2 approved for age 5+ years, 4FPTA (500-4k Hz) ≥ 90 dB HL, $\leq 5\%$ open-set word rec




SSD CI Outcomes: Spatial Hearing



SSD CI Outcomes: Spatial Hearing


B. CI benefit



- 1.6 dB CI benefit with co-located target/masker (front)
- 2.5 dB CI benefit with masker on CI side
- 3.5 dB CI benefit with masker on NH side

→ Benefit of CI in diffuse noise, no interference of CI, exhibits binaural effects

SSD CI Outcomes: SSQ



Summary

- CI candidacy reduced to 9 months
 - Evidence supports better outcomes in vocabulary, expressive and receptive language, and speech recognition for earlier implantation
 - Future directions – address gap between maximum aided % for candidacy vs. typical CI performance
- CI for SSD is the only intervention that provides stimulation of deaf ear
 - Evidence of CI benefit and no interference in complex listening environments
 - Future directions – address gap in candidacy age vs. standard candidacy age and critical period for binaural development



Part 3
What is on the Horizon?





Where Are We Headed?

- Improved sound fidelity (signal processing, microphones, electrode array designs, pulse designs)
- Robotic-assisted surgery
- Continued work on totally implantable CIs (battery, microphone)
- Gene therapy



Improved Sound Fidelity



Cochlear

- Nucleus 8 (waterproof)
 - Bluetooth LE Audio Technology --> Auracast compatible
 - SCAN 2 (SCAN was industry's first automatic scene classifier)
 - SmartSound iQ
- Nucleus 8 Hybrid
- Kanso 3 (waterproof)
 - Release mid 2025
- Nexa Internals
 - CI 1012 (contour advance), CI1022 (slim straight), CI1032 (slim modiolar)

Improved Sound Fidelity



Med-EI

- Sonnet 3 (waterproof)
 - Integrated direct streaming
 - Automatic Sound Management (ASM 3.0)
 - Adaptive intelligence
 - Fine hearing
 - Compatible with any hearing aid
 - Enhanced noise reduction
- Synchrony 2
 - 720-degree insertion depth
 - Anatomy-based fitting (OTOPLAN)
 - MRI conditional at 3.0 Tesla w/o magnet removal (rotating, self-aligning)
 - Flex soft (26.4 mm stimulation range)



Minimize Insertion Trauma



*Fig 4, Adunka & Kiefer (2006) OHNS, 135, p. 380
Med-El FLEX; BM rupture basal turn*

OTOPLAN

<https://www.medel.pro/products/otoplan>

- Cochlear duct length ranges from 25-36 mm
- Patient-specific 3D reconstruction
- Better selection of electrode array length
- Prediction of angular insertion depth and tonotopic frequency
- Simulated 3D electrode insertion
- Optimize insertion angle

FLEX34


FLEXSOFT

FLEX28

FLEX26


FLEX24

FLEX20




Robotic-Assisted CI Surgery

- OTODRIVE
 - Developed by Med-EL and CASCINATION
 - Connects with OTOPLAN
 - Slow, controlled electrode insertion



Robotic-Assisted CI Surgery

- HEARO
 - Minimally invasive access to inner ear
 - Minimize damage to facial nerve and chorda tympani
 - Used in conjunction with OTOPLAN
 - Real-time neural monitoring, imaging, and torque drilling



<https://www.cascination.com/en/hearo#:~:text=Cochlear%20implantation%20is%20one%20of,to%20the%20middle%20ear%20cavity>



Robotic-Assisted CI Surgery

- IotaSoft Insertion System

- FDA cleared in 2021
- Thumb-sized robot to precisely guide placement of cochlear implants
- Temporarily attaches to mastoid during surgery
- 10x slower insertion than surgeon, which has shown to better preserve the inner ear
- Prospective, single arm, open label study (Gantz et al., 2023)




FIG. 1. *A*, Labeled diagram of the single-use robotic-assisted cochlear implant electrode array insertion device. *B*, Intraoperative photomicrograph of the electrode array insertion device loaded with a cochlear implant electrode array during a left-sided transmastoid facial recess approach, ready for insertion.




Totally Implantable CIs

- Envoy Medical
 - FDA approval in November 2024 for staged clinical study of the Acclaim fully implantable CI (currently an investigational device)
 - Received the Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) in 2019



Totally Implantable CIs

- Envoy Medical
 - Piezoelectric sensor on incus designed to leverage the natural anatomy of the ear to capture sound (no external microphone)
 - ME sensor → implanted processor → intracochlear electrode array




Totally Implantable CIs


- Med-EI
 - Device is Mi2000
 - Similar to Cochlear's TICI (subdermal mic, option of external processor wear)
 - Comparable outcomes to traditional CI users
 - Improved comfort, satisfaction, and quality of life

Lefebvre et al., 2025

Lefebvre et al., 2025
 Fig 1 (right)
 Fig 2 (left)



TICl External



Pre-op unaided Pre-op aided TICl External

Gene Therapy

- ~80% of prelingual deafness is recessive genetic
- What is otoferlin?
 - Protein expressed in IHCs that mediates synaptic vesicle fusion
 - Recessive, DFNB9
 - Results in congenital severe-profound SNHL
- Otoferlin-based gene therapy with four clinical trials:
 - Akouos (n=2)
 - Fudan University (n=11)
 - Regeneron (n=1)
 - Southeast University/Otovia Therapeutics (n=3)
- Dual rAAV approach
- No dosage-related toxicity or severe adverse events
- Variability in outcomes from near-normal thresholds to moderate SNHL (from severe-profound)



Gene Therapy

- Single local injection of adeno-associated virus (AAV) vectors
 - Round window injection




Fig 4, Qi et al. (2024) *Advanced Science*

5 y/o patient







Fig 5, Qi et al. (2024) Advanced Science

8 y/o patient








Fig 6, Qi et al. (2024) Advanced Science

Gene Therapy: Remaining Questions

- Is a single dose sufficient for the lifetime?
- If only one cochlea is treated, can the other be treated later?
- Would redosing work if hearing declines?
- Will the treated ear be more (or less) susceptible to NIHL, aging, or ototoxicity?

References

- Adunka, O. F., Pillsbury, H. C., Adunka, M. C., & Buchman, C. A. (2010). Is electric acoustic stimulation better than conventional cochlear implantation for speech perception in quiet?. *Otology & Neurotology*, 31(7), 1049-1054.
- Arndt et al. (2015). Cochlear implantation in children with single-sided deafness: Does aetiology and duration of deafness matter? *Audiol Neurotol* 20(1), 21-30.
- Arndt, S., Laszig, R., Aschendorff, A., Hassepass, F., Beck, R., & Wesarg, T. (2017). Cochlear implant treatment of patients with single-sided deafness or asymmetric hearing loss. *Hno*, 65(Suppl 2), 98-108.
- Brigande, J. V. (2024). Otoferlin gene therapy restores hearing in deaf children. *Molecular Therapy*, 32(4), 859-860.
- Briggs et al. (2008). Initial Clinical Experience with a totally implantable cochlear implant research device. *Otol. Neurotol.* 29, 114-119.
- Burian et al. (1979).
- Dewyer et al. (2021). Pediatric single-sided deafness: A review of prevalence, radiologic findings, and cochlear implant candidacy. *Ann Otol Rhin Laryngol* 1-6.
- Dowell RC, Seligman PM, Blamey PJ, Clark GM. Evaluation of a Two-Formant Speech-Processing Strategy for a Multichannel Cochlear Prosthesis. *Annals of Otology, Rhinology & Laryngology*. 1987;96(1_suppl):132-134. doi:10.1177/00034894870960S171
- Cohen et al. (1990). Pediatric anesthesia morbidity and mortality in the perioperative period. *Anesth. Analg.* 70, 160-167.
- Colletti et al. (2011). Estimated net savings to society from cochlear implantation in infants: A preliminary analysis. *Laryngoscope* 121, 2455-2460.
- Cosetti & Roland (2010). Cochlear implantation in the very young child: Issues unique to the under-1 population. *Trends Amplif.* 14, 46-57.



References

- Gantz, J. A., Gantz, B. J., Kaufmann, C. R., Henslee, A. M., Dunn, C. C., Hua, X., & Hansen, M. R. (2023, January 1). *A steadier hand: The first human clinical trial of a single-use robotic-assisted surgical device for cochlear implant electrode array insertion*. *Otology & neurotology Hearo – robotic cochlear implantation*. Robotic Cochlear Implantation. (n.d.).
<https://www.cascination.com/en/hearo#:~:text=Cochlear%20implantation%20is%20one%20of,to%20the%20middle%20ear%20cavity>.
- Keenan et al. (1991). Frequency of anesthetic cardiac arrests in infants: Effect of pediatric anesthesiologists. *J. Clin. Anesth.* 3, 433-437.
- Landegger, L. D., Reisinger, E., Lallemand, F., Hage, S. R., Grimm, D., & Cederroth, C. R. (2024, November 8). *The rise of cochlear gene therapy*. *Molecular Therapy*.
<https://www.sciencedirect.com/science/article/pii/S1525001624007391>
- Lee et al. 2020. Consistent and chronic cochlear implant use partially reverses cortical effects of single sided deafness in children. *Sci Rep* 10, 21526.
- Lefebvre, P. P., Müller, J., Mark, G., Schwarze, F., & Hochmair, I. (2025, January 8). *Rehabilitation of human hearing with a totally implantable cochlear implant: A feasibility study*. *Nature News*.
<https://www.nature.com/articles/s43856-024-00719-0>
- Lesinski-Schiedat et al. (2004). Paediatric cochlear implantation in the first and in the second year of life: A comparative study. *Cls Int.* 5, 146-159.
- Litovsky, R. Y., Goupell, M. J., Godar, S., Grieco-Calub, T., Jones, G. L., Garadat, S. N., ... & Misurelli, S. (2012). Studies on bilateral cochlear implants at the University of Wisconsin's Binaural Hearing and Speech Laboratory. *Journal of the American Academy of Audiology*, 23(06), 476-494.
- Litovsky, R. Y., Parkinson, A., Arcaroli, J., Peters, R., Lake, J., Johnstone, P., & Yu, G. (2004). Bilateral cochlear implants in adults and children. *Archives of Otolaryngology–Head & Neck Surgery*, 130(5), 648-655.



References

- Miyamoto et al. (2008). Language skills of profoundly deaf children who received cochlear implants under 12 months of age: A preliminary study. *Acta Otolaryngol.* 128, 373-377.
- Powell, A. (2024, December 12). *Experimental gene therapy enables hearing in five children born deaf*. Harvard Medical School. <https://hms.harvard.edu/news/experimental-gene-therapy-enables-hearing-five-children-born-deaf>
- Roland et al. (2009). Cochlear implantation in the very young child: Long-term safety and efficacy. *Laryngoscope* 119, 2205-2210.
- Rubinstein, J. T., Parkinson, W. S., Lowder, M. W., Gantz, B. J., Nadol Jr, J. B., & Tyler, R. S. (1998). Single-channel to multichannel conversions in adult cochlear implant subjects. *Otology & Neurotology*, 19(4), 461-466.
- Teagle et al (2019). Pediatric cochlear implantation: A quarter century in review. *CIs Int* 20(6), 288-298.
- Tyler, R. S., Abbas, P., Tye-Murray, N., Gantz, B. J., Knutson, J. F., McCabe, B. F., ... & Kuk, F. (1988). Evaluation of five different cochlear implant designs: audiologic assessment and predictors of performance. *The Laryngoscope*, 98(10), 1100-1106.
- Van de Heyning, P., Vermeire, K., Diebl, M., Nopp, P., Anderson, I., & De Ridder, D. (2008). Incapacitating unilateral tinnitus in single-sided deafness treated by cochlear implantation. *Annals of Otology, Rhinology & Laryngology*, 117(9), 645-652.
- Von Ilberg, C., Kiefer, J., Tillein, J., Pfenningdorff, T., Hartmann, R., Stürzebecher, E., & Klinke, R. (1999). Electric-acoustic stimulation of the auditory system: New technology for severe hearing loss. *ORL*, 61(6), 334-340.
- Wolfe, J., Baker, S., Caraway, T., Kasulis, H., Mears, A., Smith, J., ... & Wood, M. (2007). 1-year postactivation results for sequentially implanted bilateral cochlear implant users. *Otology & Neurotology*, 28(5), 589-596.



Questions?

